Ophthalmology Times

Ocular Therapeutix enrolls first patient in SOL-X long-term extension trial for AXPAXLI

Ocular Therapeutix has initiated a long-term extension trial evaluating the investigational intravitreal therapy AXPAXLI in ...
Seeking Alpha

Outlook Therapeutics: August PDUFA May Be A Buy With Some Caveats

Outlook Therapeutics (OTLK) is developing the first ophthalmic formulation of anti-VEGF monoclonal antibody bevacizumab. This has been a long way in the making. The BLA is supported by three phase 3 ...

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...
ascopubs.org

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

PURPOSE: We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer. PATIENTS AND METHODS: ...
ascopubs.org

Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.

Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM). This is an ASCO Meeting Abstract from the 2013 ...